Amorepacific Corporation   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Seoul Korea, Republic of (1945)
Status: No NME R&D (1945)

Organization Overview

First Clinical Trial
2010
NCT01264224
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Amorepacific Corporation | Amorepacific R&D Center | Amorepacific R&I center

Active Ingredients

Drugs in Phase 3 Trials (1)

pac-14028 (12 trials)

Drugs in Phase 2 Trials (3)

metronidazole (flagyl) (1 trial)

pimecrolimus (elidel) (1 trial)

valproic acid (depakene) (1 trial)

Drugs in Phase 1 Trials (2)

sodium chloride (1 trial)

sodium monododecyl sulfate (1 trial)

Drugs in Other Trials (5)

collagen (1 trial)

gamma-aminobutyric acid (1 trial)

ginseng (1 trial)

heukcha extracts (1 trial)

tea (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alopecia (Phase 2)

Dermatitis (Phase 3)

Dermatitis, Atopic (Phase 3)

Dermatitis, Seborrheic (Phase 2)

Eczema (Phase 3)

Pruritus (Phase 2)

Rosacea (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 20
  • # of Trial APIs: 11